MA50070A - Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie - Google Patents

Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie

Info

Publication number
MA50070A
MA50070A MA050070A MA50070A MA50070A MA 50070 A MA50070 A MA 50070A MA 050070 A MA050070 A MA 050070A MA 50070 A MA50070 A MA 50070A MA 50070 A MA50070 A MA 50070A
Authority
MA
Morocco
Prior art keywords
carcinotherapy
association
immune checkpoint
histone deacetylase
deacetylase inhibitor
Prior art date
Application number
MA050070A
Other languages
English (en)
Inventor
René Bartz
Roland Baumgartner
Susanne Danhauser-Riedl
Svetlana Hamm
Frank Hermann
Original Assignee
4Sc Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Ag filed Critical 4Sc Ag
Publication of MA50070A publication Critical patent/MA50070A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050070A 2017-09-08 2018-09-07 Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie MA50070A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190242 2017-09-08
EP17190238 2017-09-08
EP17190233 2017-09-08

Publications (1)

Publication Number Publication Date
MA50070A true MA50070A (fr) 2020-07-15

Family

ID=63442655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050070A MA50070A (fr) 2017-09-08 2018-09-07 Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie

Country Status (14)

Country Link
US (1) US20200261418A1 (fr)
EP (1) EP3678740A1 (fr)
JP (1) JP2020533320A (fr)
KR (1) KR20200051712A (fr)
CN (1) CN111432884A (fr)
AU (1) AU2018330492A1 (fr)
CA (1) CA3075215A1 (fr)
IL (1) IL273092A (fr)
MA (1) MA50070A (fr)
MX (1) MX2020002585A (fr)
RU (1) RU2020113009A (fr)
SG (1) SG11202001760VA (fr)
TW (1) TW201919614A (fr)
WO (1) WO2019048629A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202114659A (zh) * 2019-10-02 2021-04-16 德商４Ｓｃ製藥公司 用於癌症治療之含ｈｄａｃ抑制劑、ｃｔｌａ—４抑制劑及ｐｄ—１抑制劑或ｐｄ—ｌ１抑制劑之組合
CN113288871B (zh) * 2021-05-28 2022-09-16 华中科技大学 用于调控表观遗传与免疫检查点的药物组合物脂质体制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327269T3 (es) * 2005-03-15 2009-10-27 4Sc Ag N-sulfonilpirroles y su utilizacion como inhibidores de la histona desacetilasa.
EP2100882A1 (fr) * 2008-03-12 2009-09-16 4Sc Ag Sels d'acrylamide (E) -N -(2-Amino-phényl) -3-{1-[4-(1-méthyl-1H-pyrazol-4-yl)-benzènesulfonyl] -1H-pyrrol-3-yl}
EP3270966B1 (fr) * 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc. Association d'un inhibiteur de l'histone désacétylase (hdac) avec un anticorps anti-pd-1 pour le traitement du cancer, la combinaison ne comprenant pas de 5-azacytidine.
WO2017035453A1 (fr) * 2015-08-26 2017-03-02 The Johns Hopkins University Compositions et méthodes de traitement de tumeurs solides

Also Published As

Publication number Publication date
RU2020113009A (ru) 2021-10-08
IL273092A (en) 2020-04-30
JP2020533320A (ja) 2020-11-19
AU2018330492A1 (en) 2020-03-19
CA3075215A1 (fr) 2019-03-14
US20200261418A1 (en) 2020-08-20
KR20200051712A (ko) 2020-05-13
WO2019048629A1 (fr) 2019-03-14
TW201919614A (zh) 2019-06-01
SG11202001760VA (en) 2020-03-30
CN111432884A (zh) 2020-07-17
RU2020113009A3 (fr) 2021-12-29
EP3678740A1 (fr) 2020-07-15
MX2020002585A (es) 2020-07-22

Similar Documents

Publication Publication Date Title
MA43037A (fr) Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
SG11202101534UA (en) Road segment similarity determination
FR3027496B1 (fr) Dispositif de conditionnement et d'application
MA47305A (fr) Inhibiteurs bicycliques d'histone désacétylase
FR3026447B1 (fr) Dispositif formant cle pour le maintien d'un frein d'ecrou
MA53129A (fr) Inhibiteurs de l'histone désacétylase
FR3022922B1 (fr) Dispositif pour repandre un enrobe bitumineux a partir d'un film d'epaisseur determinee de l'enrobe, procede de mise en œuvre.
MA53128A (fr) Inhibiteurs bicycliques de l'histone désacétylase
FR3021373B1 (fr) Dispositif d'articulation a rotule pour une turbomachine.
FR3040594B3 (fr) Dispositif passe-lacet pour chaussure et chaussure comprenant ledit dispositif passe-lacet
MA49839A (fr) Inhibiteurs bicycliques d'histone désacétylase
MA50070A (fr) Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie
FR3004810B1 (fr) Utilisation de biomarqueurs de la barriere pour l'evaluation de l'efficacite d'actifs.
FR3029080B1 (fr) Dispositif de conditionnement et d'application
FR3019519B1 (fr) Ligne d'ancrage pour support flottant comprenant un dispositif elastique
FR3035929B1 (fr) Palier comprenant un flasque d'etancheite elastique
FR3028728B1 (fr) Dispositif de conditionnement et d'application
FR3018672B1 (fr) Dispositif de conditionnement et d'application.
FR3057904B1 (fr) Dispositif d'amortissement ameliore pour compresseur de turbomachine
FR3001543B1 (fr) Dispositif pour la mise sous traction ou sous compression d'une eprouvette
FR3058613B3 (fr) Dispositif d'abreuvement transportable notamment pour equides
FR3032803B1 (fr) Dispositif pour la caracterisation d'ondes electromagnetiques.
FR3016622B1 (fr) Dispositif destine a equiper les enrenements equestres pour en faciliter et en ameliorer l'utilisation
MA49389A (fr) Dispositif d'inhibition d'un détrompeur de réservoir
UA39293S (uk) Логотип «сoffee street»